Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:Treatment after first relapsedOptimal use of CAR T-cell therapyWhen to use selinexor and belantamab mafodotinCOVID-19 vaccinations for patients with myelomaPresenters:Paul G. Richardson, MDR. J. Corman Professor of MedicineHarvard Medical SchoolClinical Program LeaderDirector of Clinical ResearchJerome Lipper Multiple Myeloma CenterDana-Farber Cancer InstituteBoston, MassachusettsNina Shah, MDProfessor of Clinical MedicineDivision of Hematology-OncologyDepartment of MedicineUniversity of California San FranciscoSan Francisco, CaliforniaPeter M. Voorhees, MDDirector, Medical Operations and Outreach ServicesDepartment of Hematology/OncologyLevine Cancer Institute, Atrium HealthCharlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.Link to full program:https://bit.ly/2UIhXcL